Krystal Biotech, Inc. (KRYS)

How it makes money

All revenue is net product revenue from a single medicine, VYJUVEK, sold on prescription to a very small population of diagnosed DEB patients and paid for by third-party payors — commercial insurers, Medicare and Medicaid in the US, national health systems in Europe and Japan. Because the therapy is redosable and applied to wounds repeatedly rather than given once, a treated patient generates recurring revenue for as long as treatment continues, which makes the model closer to a chronic-therapy annuity than to a one-shot gene therapy. Sales flow through a narrow distribution chain: a third-party packager and logistics provider ship to a limited number of specialty pharmacies (which mix the product and can administer it at the patient's home), plus a limited number of hospitals and distributors; outside the US, Europe and Japan, regional specialty distributors handle commercialisation. Revenue is recorded net of rebates, prompt-pay discounts and returns. FY2025 net product revenue was $389.1 million, against $290.5 million in FY2024 and $50.7 million in FY2023, at a 94% gross margin in FY2025. The company also sold its FDA Rare Pediatric Disease Priority Review Voucher for $100 million in 2023, but that was a one-off gain, not recurring revenue.

Krystal's protection is regulatory and legal rather than commercial. VYJUVEK is the first and, so far, the only corrective medicine approved for DEB in the US and the EU; it carries FDA Orphan Drug Designation, which blocks approval of the same biologic for the same indication for seven years, and as a biologic it should qualify for the 12-year exclusivity period under the BPCIA. That sits on top of patents covering the engineered HSV-1 platform and the product, plus a manufacturing base the company built in-house (the ANCORIS and ASTRA CGMP plants) specifically to keep quality control and process know-how inside the company. Prescribing is also concentrated: DEB is diagnosed and followed by a small number of specialist centres, and the field force has already identified most of the treatable population, which is hard for a newcomer to replicate quickly. The reason this is narrow rather than wide is that the whole advantage rests on one product in one indication with a fixed exclusivity clock: the filing itself warns that biosimilar competition could arrive sooner than expected, that competitors are developing alternative autologous and palliative gene-therapy approaches for DEB, and that many of them have far greater financial and technical resources.

Demand for VYJUVEK does not follow the economic cycle. DEB is a severe inherited disease present from birth; patients need wound treatment regardless of what the economy is doing, and the therapy is redosable, so a treated patient keeps consuming product week after week. What actually drives revenue is a different set of variables: how many DEB patients are found and diagnosed (the company estimates over 3,000 in the US and over 9,000 worldwide, with more than 1,000 already identified in Germany and France), how quickly each new country agrees a reimbursement price, and how many identified patients start and stay on treatment. That makes the growth path lumpy and political rather than cyclical — the filing notes pricing negotiations expected to run until at least the second half of 2026 in Germany and until 2027 in France, with an Italian launch targeted for the second half of 2026. The corresponding downside is that government cost-containment and payer policy, not consumer weakness, are what can knock demand off course.

Key risks

• Everything depends on one product — The company states it is substantially dependent on the commercial success of VYJUVEK: its near-term prospects, its ability to fund development of the pipeline and its future growth all rest on that single medicine. It gives no assurance of obtaining approval in jurisdictions beyond the US, EU and Japan, and notes that many of the factors determining commercial success are beyond its control.
• A very small number of distribution partners — Krystal relies on a small number of third parties to get VYJUVEK to US patients — one packaging company, one third-party logistics provider, a limited number of specialty pharmacies and a limited number of hospitals and distributors. Failure to maintain those agreements, or to coordinate the distribution and financial systems behind them, could compromise sales and even the accuracy of reported product revenue. Outside the US, Europe and Japan the company depends on regional specialty distributors it may not be able to sign on favourable terms, and which may under-resource, mis-report or discontinue their selling effort.
• Coverage, reimbursement and price controls — The company flags significant uncertainty over third-party coverage and reimbursement for newly approved products. Obtaining coverage is slow and costly and may require cost-effectiveness data it cannot supply; even where coverage exists it may be narrower than the approved label or paid at a rate that does not cover costs. Outside the US, operations face extensive government price controls: EU member states run positive and negative list systems under which a product can only be marketed once a reimbursement price has been agreed, and the filing notes that European reimbursement agencies may be more conservative than CMS.
• The addressable market may be smaller than estimated — Market-size estimates for rare diseases rest on limited epidemiological data and on assumptions about label scope, pricing and reimbursement that may prove wrong. The company adds that the number of patients actually treated can fall short of the addressable market: therapies are not widely available or reimbursed in underdeveloped markets, advanced disease progression may have caused irreversible damage that limits benefit, and some patients' immune systems may block delivery of the gene therapy to the target tissue.
• Competition and biosimilars — The company is aware of several firms and institutions developing alternative autologous, palliative or gene-therapy approaches for DEB, many with far larger research, clinical, marketing and manufacturing organisations. It also warns that its expected 12-year biologic exclusivity could be shortened by legislation or by the FDA declining to treat its genetic medicines as reference products, and that recent draft FDA guidance could lower development burdens and accelerate biosimilar competition.
• A novel platform makes regulatory timing unpredictable — The gene therapy platform is based on novel technology, which the company says makes it difficult to predict the time and cost of obtaining regulatory approvals for its product candidates. It also notes that ethical, legal and social concerns around the genetic testing patients must undergo before receiving VYJUVEK could reduce demand.
• Cybersecurity along the reimbursement chain — The company cites a concrete precedent: in 2024 its specialty pharmacy provider was hit by a cybersecurity incident that delayed reimbursement approvals and had a negative impact on product revenue. It warns that neither its own systems nor those of suppliers, distributors, manufacturers and vendors can be guaranteed against ransomware, phishing or exploited software vulnerabilities.
• Managing rapid growth and a young commercial organisation — Krystal has limited experience as a commercial company and has gone through a period of heavy expansion in personnel, facilities and overhead — building its own manufacturing plants and its own sales, marketing, market access and medical affairs teams in the US, Europe and Japan. It warns that its current management, finance and IT systems may not be adequate for the growth expected, and that if a launch disappoints, the investment in that commercial infrastructure would be lost if the staff cannot be retained or redeployed.

Top customers account for 75% of revenue

Customer concentration is extreme, though it is improving. In FY2025 approximately 75% of net product revenue came from a single customer in the US; no other customer exceeded 10%. That share was 87% in FY2024 and 100% in FY2023, so the international launches are gradually diluting the dependence. The 'customer' here is a distribution counterparty — a specialty pharmacy or distributor — not the end payer or patient, but the accounting exposure is real: accounts receivable relating to VYJUVEK stood at $127.4 million at 31 December 2025 on payment terms generally of 90 days or less, and the company records two customers individually accounting for 10% or more of that receivable balance. It reports no historical write-offs and recorded no allowance for credit losses.